Alterações fisiológicas e comportamentais de bovinos de corte após o manejo de castração / Physiological and behavioral changes of beef cattle after castration management

Objetivou-se avaliar o desempenho, parâmetros fisiológicos e temperamentais de bovinos de corte não castrados ou submetidos à castração cirúrgica ou à imunocastração. O período experimental foi dividido em dois subperíodos de observações: primeiros 15 dias pós-castração (período de cicatrização) e os 25 dias seguintes à cicatrização. Nos primeiros 15 dias de avaliação, os animais não castrados obtiveram maior ganho médio diário de peso em relação aos castrados cirurgicamente. A frequência cardíaca foi maior para os animais castrados cirurgicamente, com 126,51 batimentos/minuto, em relação aos demais tratamentos. A distância de fuga foi superior para os novilhos castrados cirurgicamente, com valor de 12,22 metros. Nos 25 dias seguintes à castração cirúrgica, o ganho médio diário de peso foi superior nos bovinos castrados cirurgicamente em relação aos bovinos não castrados ou imunocastrados. A velocidade de fuga, no segundo subperíodo de avaliação, foi superior nos bovinos castrados em relação aos não castrados. O período imediato à castração, os primeiros 15 dias, prejudicou o ganho médio diário e o ganho de peso total, o que causou maior reatividade, com alterações nos parâmetros fisiológicos e temperamentais de bovinos castrados cirurgicamente em comparação com bovinos não castrados, entretanto, transcorrido o período de cicatrização, essas diferenças diminuíram ou desapareceram.(AU)

The aim of this study was to evaluate the performance, physiological and temperamental parameters of uncastrated beef cattle or those submitted to surgical castration or immunocastration, in the post-castration period. The experimental period was divided into two subperiods of observations: the first 15 days post-castration (healing period) and the 25 days following healing. In the first 15 days of evaluation, the non-castrated animals obtained a greater average daily gain of weight in relation to surgically castrated. The heart rate was higher for surgically castrated animals with 126,51 beats/minute, compared to the other treatments. The distance of escape was higher for the surgically castrated steers, with a value of 12,22 meters, when compared to the other groups studied. During the next 25 days of surgical castration, the mean daily gain of weight was higher in surgically castrated cattle than in non-castrated or immunocastrated cattle. The escape velocity, in the second evaluation subperiod, was superior in the castrated cattle, in relation to the not castrated. The immediate castration period, the first 15 days, altered the mean daily gain and the total weight gain, the physiological and temperamental parameters of surgically castrated cattle, however, after the healing period, these differences diminish or disappear.(AU)

Solubilization of human erythrocyte membranes by ASB detergents.

Understanding the membrane solubilization process and finding effective solubilizing agents are crucial challenges in biochemical research. Here we report results on the interaction of the novel linear alkylamido propyl dimethyl amino propanosulfonate detergents, ASB-14 and ASB-16, with human erythrocyte membranes. An estimation of the critical micelle concentration of these zwitterionic detergents (ASB-14 = 100 microM and ASB-16 = 10 microM) was obtained using electron paramagnetic resonance. The amount of proteins and cholesterol solubilized from erythrocytes by these detergents was then determined. The hemolytic activities of the ASB detergents were assayed and the detergent/lipid molar ratios for the onset of hemolysis (Re sat) and total lysis (Re sol) were calculated, allowing the determination of the membrane binding constants (Kb). ASB-14 presented lower membrane affinity (Kb = 7050 M(-1)) than ASB-16 (Kb = 15610 M(-1)). The amount of proteins and cholesterol solubilized by both ASB detergents was higher while Re sat values (0.22 and 0.08 detergent/lipid for ASB-14 and ASB-16, respectively) were smaller than those observed with the classic detergents CHAPS and Triton X-100. These results reveal that, besides their well-known use as membrane protein solubilizers to enhance the resolution of two dimensional electrophoresis/mass spectrometry, ASB-14 and ASB-16 are strong hemolytic agents. We propose that the physicochemical properties of ASB detergents determine their membrane disruption efficiency and can help to explain the improvement in the solubilization of membrane proteins, as reported in the literature.

Solubilization of human erythrocyte membranes by ASB detergents

Understanding the membrane solubilization process and finding effective solubilizing agents are crucial challenges in biochemical research. Here we report results on the interaction of the novel linear alkylamido propyl dimethyl amino propanosulfonate detergents, ASB-14 and ASB-16, with human erythrocyte membranes. An estimation of the critical micelle concentration of these zwitterionic detergents (ASB-14 = 100 µM and ASB-16 = 10 µM) was obtained using electron paramagnetic resonance. The amount of proteins and cholesterol solubilized from erythrocytes by these detergents was then determined. The hemolytic activities of the ASB detergents were assayed and the detergent/lipid molar ratios for the onset of hemolysis (Re sat) and total lysis (Re sol) were calculated, allowing the determination of the membrane binding constants (Kb). ASB-14 presented lower membrane affinity (Kb = 7050 M-1) than ASB-16 (Kb = 15610 M-1). The amount of proteins and cholesterol solubilized by both ASB detergents was higher while Re sat values (0.22 and 0.08 detergent/lipid for ASB-14 and ASB-16, respectively) were smaller than those observed with the classic detergents CHAPS and Triton X-100. These results reveal that, besides their well-known use as membrane protein solubilizers to enhance the resolution of two dimensional electrophoresis/mass spectrometry, ASB-14 and ASB-16 are strong hemolytic agents. We propose that the physicochemical properties of ASB detergents determine their membrane disruption efficiency and can help to explain the improvement in the solubilization of membrane proteins, as reported in the literature.

Comparative bioavailability of three ibuprofen formulations in healthy human volunteers.

OBJECTIVE: To assess the bioequivalence of three ibuprofen formulations (Test formulation: ibuprofen (400 mg capsule) manufactured by Cardinal Health Brasil 402 Ltda. (Sorocaba, Brazil) and licensed to Boehringer Ingelheim do Brasil Quim. e Farm. Ltda. (SA poundo Paulo, Brazil); Reference formulation (1): ibuprofen (AdvilA(R); 2 A 200 mg coated tablet) from Wyeth-Whitehall Ltda. (Itapevi, Brazil); Reference formulation (2): ibuprofen (AliviumA; 8 ml A 50 mg/ml solution) from Schering Plough S.A. (Rio de Janeiro, Brazil)) in 24 healthy volunteers of both sexes. METHODS: The study was conducted using an open, randomized, three-period crossover design with at least 5-day washout interval. Plasma samples were obtained over a 24-h period. Plasma ibuprofen concentrations were analyzed by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) with negative ion electrospray ionization using multiple reaction monitoring (MRM). The following pharmacokinetic parameters were obtained from the ibuprofen plasma concentration vs. time curves: AUC(last), AUC(trunctmax), AUC(inf) and C(max). RESULTS: The limit of quantification for ibuprofen was 0.1 microg A ml(1). The geometric mean with corresponding 90% confidence interval (CI) for Test/Reference (1) percent ratios were 114.24% (90% CI = 105.67, 123.50%) for C(max), 98.97% (90% CI = 94.69, 103.44%) for AUC(last) and 99.40% (90% CI = 95.21, 103.78%) for AUC(inf). The geometric mean and respective 90% confidence interval (CI) for Test/Reference (2) percent ratios were 108.38% (90% CI = 100.19, 117.25%) for C(max), 100.79% (90% CI = 96.39, 105.40%) for AUC(last) and 101.26% (90% CI = 96.94, 105.77%) for AUC(inf); t(max) for the 400 mg Test capsule was shorter than that for the 2 A 200 mg Reference (1) tablets (p < 0.002). CONCLUSION: Since the 90% CI for AUC(last), AUC(inf) and Cmax ratios were within the 80 - 125% interval proposed by the US FDA, it was concluded that ibuprofen formulation manufactured by Cardinal Health Brasil 402 Ltda. and licensed to Boehringer Ingelheim do Brasil Quim. e Farm. Ltda. is bioequivalent to the AdvilA and AliviumA formulations with regard to both the rate and the extent of absorption.